Related references
Note: Only part of the references are listed.Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors
F. Morgillo et al.
BRITISH JOURNAL OF CANCER (2011)
STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17
Bingbing Dai et al.
CANCER RESEARCH (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
Jaafar Bennouna et al.
INVESTIGATIONAL NEW DRUGS (2011)
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
Tanios Bekaii-Saab et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Impact of Age at Diagnosis on Prostate Cancer Treatment and Survival
Seth K. Bechis et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Jonathan R. Dry et al.
CANCER RESEARCH (2010)
A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens
John D. Hainsworth et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non-Small Cell Lung Cancer Cell Lines
Edward B. Garon et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras-Mutated Colorectal Cancer
John J. Tentler et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)
Jieru Meng et al.
CANCER BIOLOGY & THERAPY (2009)
The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts
Aoife M. Shannon et al.
CLINICAL CANCER RESEARCH (2009)
Protein kinase A as a biological target in cancer therapy
Silvio Naviglio et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2009)
Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERKI/2 signalling and/or strong P13K signalling in colorectal cancer cell lines
Kathryn Balmanno et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
Alex A. Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
RAR and RXR modulation in cancer and metabolic disease
Lucia Altucci et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases:: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models
Barry R. Davies et al.
MOLECULAR CANCER THERAPEUTICS (2007)
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Erminia Massarelli et al.
CLINICAL CANCER RESEARCH (2007)
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor
Tammie C. Yeh et al.
CLINICAL CANCER RESEARCH (2007)
Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma
Hung Huynh et al.
MOLECULAR CANCER THERAPEUTICS (2007)
AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma
Hung Huynh et al.
MOLECULAR CANCER THERAPEUTICS (2007)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Intracellular signal transduction pathway proteins as targets for cancer therapy
AA Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
W Pao et al.
PLOS MEDICINE (2005)
MEK inhibitors: A therapeutic approach to targeting the Ras-MAP kinase pathway in tumors
JS Sebolt-Leopold
CURRENT PHARMACEUTICAL DESIGN (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Modelling the molecular circuitry of cancer
WC Hahn et al.
NATURE REVIEWS CANCER (2002)
Blocking oncogenic Ras signaling for cancer therapy
AA Adjei
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Targeting of epidermal growth factor receptor and protein kinase A: Molecular basis and therapeutic applications
G Tortora et al.
ANNALS OF ONCOLOGY (2000)
Share Paper
